Ligand ID: 5FW Drugbank ID: DB01064(Isoprenaline) Indication:For the treatment of mild or transient episodes of heart block that do not require electric shock or pacemaker therapy also used in management of asthma and chronic bronchitis |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | THR A 276VAL A 353VAL A 354PHE A 652ASN A 300 | 1.72A | 16.14 | None | ||
![]() | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.59A | 15.20 | None | ||
![]() | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 6 / 12 | ASP A 390VAL B 131VAL A 405PHE A 407ASN A 447TYR A 674 | 1.52A | 16.14 | None | ||
![]() | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.59A | 15.20 | None | ||
![]() | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 6 / 12 | ASP A 390VAL B 131VAL A 405PHE A 407ASN A 447TYR A 674 | 1.51A | 16.14 | None | ||
![]() | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | THR B 859ASP A 614SER A 316SER A 596PHE A 318 | 1.78A | 13.84 | None | ||
![]() | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | ASP A 614VAL A 615SER A 596PHE A 318ASN A 317 | 1.47A | 14.00 | None | ||
![]() | 4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 6w75 | NSP16 (SARS-CoV-2) | 3 / 3 | ASN A6920TRP A6922ASP C7091 | 1.72A | 23.64 | FMT A7106 ( 4.0A)NoneNone | ||
![]() | 4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 6w75 | NSP16 (SARS-CoV-2) | 3 / 3 | ASN C6920TRP C6922ASP A7091 | 1.67A | 23.64 | FMT C7106 ( 4.1A)NoneNone | ||
![]() | 4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 3 / 3 | ASN C6920TRP C6922ASP A7091 | 1.65A | 16.33 | FMT C7103 (-4.0A)NoneNone | ||
![]() | 4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 6wkq | NSP16 (SARS-CoV-2) | 3 / 3 | ASN A6920TRP A6922ASP C7091 | 1.74A | 16.33 | FMT A7109 ( 3.9A)NoneNone | ||
![]() | 4A7T_A_5FWA1002_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 6wkq | NSP16 (SARS-CoV-2) | 3 / 3 | ASN C6920TRP C6922ASP A7091 | 1.64A | 16.33 | FMT C7106 ( 4.1A)NoneNone | ||
![]() | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | ASP A 421VAL A 424SER C 1SER C 4PHE A 415 | 1.79A | 15.20 | None | ||
![]() | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.42A | 15.20 | None | ||
![]() | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) | 7btf | NSP12NSP8 (SARS-CoV-2) | 6 / 12 | ASP A 390VAL B 131VAL A 405PHE A 407ASN A 447TYR A 674 | 1.47A | 16.14 | None | ||
![]() | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL A 405PHE A 407ASN A 447TYR A 674 | 1.43A | 16.14 | None | ||
![]() | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.42A | 16.14 | None | ||
![]() | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.43A | 15.20 | None | ||
![]() | 4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | GLU A 278LYS A 281TRP A 268GLU A 254 | 1.18A | 9.87 | None | ||
![]() | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) | 7btf | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | ASP A 421VAL A 424SER C 1SER C 4PHE A 415 | 1.78A | 15.20 | None | ||
![]() | 4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | GLU A 278LYS A 281TRP A 268GLU A 254 | 1.21A | 9.87 | None | ||
![]() | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | THR A 276VAL A 353VAL A 354PHE A 652ASN A 300 | 1.76A | 15.77 | None | ||
![]() | 4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | GLU A 278LYS A 281TRP A 268GLU A 254 | 1.56A | 9.96 | None | ||
![]() | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.45A | 15.46 | None | ||
![]() | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.37A | 15.77 | None | ||
![]() | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL A 405PHE A 407ASN A 447TYR A 674 | 1.39A | 15.77 | None | ||
![]() | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.45A | 15.46 | None | ||
![]() | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.35A | 15.77 | None | ||
![]() | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL A 405PHE A 407ASN A 447TYR A 674 | 1.42A | 15.77 | None | ||
![]() | 4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | GLU A 278LYS A 281TRP A 268GLU A 254 | 1.39A | 9.96 | None | ||
![]() | 2Y03_A_5FWA601_1 (BETA-1 ADRENERGICRECEPTOR) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 6 / 12 | ASP A 390VAL B 131VAL A 405PHE A 407ASN A 447TYR A 674 | 1.56A | 15.77 | None | ||
![]() | 2Y03_B_5FWB601_1 (BETA-1 ADRENERGICRECEPTOR) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 6 / 12 | ASP A 390VAL B 131VAL A 405PHE A 407ASN A 447TYR A 674 | 1.50A | 15.77 | None | ||
![]() | 4A7T_F_5FWF1001_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | GLU A 278LYS A 281TRP A 268GLU A 254 | 1.54A | 9.96 | None | ||
![]() | 4A7T_A_5FWA1000_1 (SUPEROXIDE DISMUTASE[CU-ZN]) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | GLU A 278LYS A 281TRP A 268GLU A 254 | 1.76A | 9.96 | None | ||
![]() | 6H7J_B_5FWB402_0 (BETA-1 ADRENERGICRECEPTOR) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.45A | 15.46 | None | ||
![]() | 6H7J_A_5FWA401_0 (BETA-1 ADRENERGICRECEPTOR) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 390VAL B 131PHE A 407ASN A 447TYR A 674 | 1.45A | 15.46 | None |